THERAPEUTIC INDICATIONS: Infections caused by germs that are sensitive to ceftriaxone, for example:
Abdominal infections (peritonitis, infections of the bile ducts and gastrointestinal tract).
Bone infections, joint, soft tissue, skin, as well as infected wounds.
Perioperative prophylaxis of infections.
Infections in patients with weakened immune systems.
Kidney infections and urinary tract.
Airway infections, particularly pneumonia, as well as infections of the throat, nose and ear.
Genital tract infections, including gonorrhea.
Lyme borreliosis from the second stage of the disease.
AMCEF® can be used alone or in combination with other antibacterial agents in prophylaxis of postoperative infections associated with cardiovascular surgery and urology and colorectal surgery.
Hypersensitivity to antibiotics caftriaxona or cephalosporin. In patients with hypersensitivity to penicillin must consider the possibility of cross-allergy. AMCEF® should not be administered with calcium-containing products and solutions particularly in infants, because the risk of precipitation of ceftriaxone calcium salt.
Hiperbilirrubinémicos newborns, especially premature babies, should not be treated with AMCEF®.
In vitro studies have shown that ceftriaxone can displace bilirubin from its serum albumin binding and in these patients may be able to develop bilirubin encephalopathy.
In intramuscular administration: We must exclude contraindications of lidocaine before the Technical administrative use of ceftriaxone.
DOSAGE AND ADMINISTRATION:
Adults and children over 12 years: The usual dose is 1-2 grams of AMCEF® once a day(every 24 hours). In severe cases or in infections caused by moderately sensitive organisms, the dose may be increased to 4 g once a day.
Duration of therapy: The duration of therapy varies according to the course of the disease. As a general antibiotic therapy is the administration of AMCEF® should continue at least for 48-72 hours after the patient is without fever or evidence has been obtained from bacterialeradication.
Combination Therapy: It has been demonstrated synergy between AMCEF® and aminoglycosides with many gram-negative bacteria under experimental conditions. Although the major activity of such combinations is not always reliable, should be considered life-threatening infections due to microorganisms such as Pseudomonas aeruginosa. Because ofphysical incompatibility, both drugs should be administered separately at the recommended dose.
Method of administration: As a general rule, the solutions may be used immediately after preparation.
Name of medicine: AMCEF®.
Comparable patent medicine: Rocephin, terbac I.M.
Active ingredient: Ceftriaxone 1.0g
Presentation: Solution for Injection
Extended-release tablets: No
Box with 1 vial with powder and
10ml vial with diluent
Made in: Mexico